The Next Vaccine Revolution
mRNA vaccines transformed infectious disease medicine during the COVID-19 pandemic, demonstrating that the technology could be developed, manufactured, and deployed at unprecedented speed. But mRNA vaccines have real limitations — they require cold-chain logistics that challenge distribution in low-resource settings, their immune responses can wane relatively quickly, and their manufacturing involves complexity that constrains production capacity.
Researchers believe the next leap may come from a surprising direction: DNA origami. Scientists are now testing a platform called DoriVac that uses folded DNA nanostructures — geometric shapes assembled from DNA strands with near-atomic precision — to deliver antigens to the immune system in a way that produces stronger and more durable responses than conventional approaches.
How DNA Origami Works in Vaccines
DNA origami is a technique in which single-stranded DNA is folded into precise two-dimensional and three-dimensional shapes using complementary short DNA strands as staples. The resulting nanostructures can be designed to almost any geometry and can be functionalized with proteins, small molecules, or other biological payloads at specific, programmable locations.
In the DoriVac platform, these nanostructures are loaded with antigenic proteins arranged in patterns that mimic how antigens appear on the surface of actual viruses. This spatial arrangement is critical. The immune system's B cells respond more vigorously to antigens displayed in repetitive, ordered arrays — similar to the surface proteins of a real pathogen — than to antigens presented in solution.
Early Results
In early studies conducted in mice and human immune cell models, DoriVac produced both strong antibody responses and robust T cell responses. The T cell response is particularly notable: mRNA vaccines excel at generating antibody responses but have variable success at producing T cell immunity, which is especially important for clearing established infections and providing long-duration protection.
The researchers reported that DoriVac's structured antigen presentation more effectively activated dendritic cells — the immune system's professional antigen-presenting cells — compared to antigen delivered in soluble form. Dendritic cell activation is a key bottleneck in generating strong T cell responses.
Manufacturing Advantages
Beyond immunological performance, the DoriVac platform may offer meaningful manufacturing advantages over mRNA vaccines. DNA is chemically more stable than RNA, reducing cold-chain requirements and extending shelf life under ambient conditions. The synthesis of DNA nanostructures can be performed using existing DNA synthesis infrastructure and does not require the specialized lipid nanoparticle formulation that mRNA vaccines depend on.
Researchers also note that the modular design of DNA origami nanostructures makes the platform inherently adaptable. Changing the antigen target requires modifying the attached payload rather than redesigning the underlying delivery system — a characteristic that could enable rapid response to emerging infectious disease threats.
Path to Clinical Trials
The DoriVac platform remains at the preclinical stage, with significant questions remaining about its behavior in human subjects and its scalability to pandemic-level production. The researchers are targeting diseases where the limitations of existing vaccine technology are most acute — HIV, Ebola, and COVID-19 variants — as initial clinical development priorities.
HIV vaccine development has challenged the field for four decades, with the difficulty of generating broadly neutralizing antibodies against the virus's rapidly mutating surface proteins remaining the central obstacle. The DoriVac approach to structured antigen presentation is one of several strategies researchers are pursuing to overcome this barrier.
This article is based on reporting by Science Daily. Read the original article.
